Moderna Shares Rebound on Promising Vaccine Data

Moderna investors have experienced significant volatility recently as the biotech company navigated both concerning safety reports and encouraging clinical developments. The stock’s dramatic movements reflect the market’s ongoing assessment of the company’s position in the evolving vaccine landscape.

The coming weeks present pivotal moments for Moderna, with a Senate hearing scheduled for September 17th followed by CDC advisory meetings on September 18th and 19th. These sessions could yield updated vaccination recommendations ahead of the fall season. Investors will be watching closely for how these developments might influence Moderna’s commercial performance, which will become clearer when the company reports quarterly results in late October.

Strong Immune Response Data Drives Recovery

On Tuesday,... Read more...